AzTrials
AzTrials

Medication AdherenceNCT01603329

Increasing Medication Adherence Through Physician Incentives and Messaging

A study testing Increasing Medication Adherence through Physician Incentives and Messaging in people with Medication Adherence, run by National Bureau of Economic Research, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for… Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Medication Adherence
What is being tested?
Increasing Medication Adherence through Physician Incentives and Messaging
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
734 participants
Where
1 siteUnited States
Study dates
Jun 2012to Mar 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Physician in the Humana network
  • Treats Humana Medicare Advantage Members
  • Has Humana Medicare Advantage members who are taking at least one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication, and who are less than 80% adherent.

Who cannot join

  • Practices with more than 10 physicians

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Humana, Inc

    Louisville, Kentucky, 40202

Other trials in United States

About this study

The goal of this project is to increase patient adherence to medication using communications and incentives for physicians. The investigators are partnering with a health insurance company, Humana Inc, to design and implement an incentives program for physicians whose patients increase their medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and/or cholesterol (statins) medication. The investigators will use behavioral economics to explore the best way to communicate the incentives to the physicians.

Read the detailed description

Traditional economics would suggest that the best way to maximize adherence would be to give physicians financial incentives to improve adherence to all relevant drugs, and that communications to physicians should emphasize all of the relevant drugs. Behavioral economics suggests theory suggests that if you emphasize everything, then you are effectively emphasizing nothing. Behavioral econonmics would suggest to maximize adherence one should give physicians financial incentives for improving adherence for a small number of relevant drugs, and communications to physicians should emphasize a small number of the relevant drugs. This allows physicians to focus their energy and reduces the probability that they will give up because they're overwhelmed, or in other words, avoid the phenomenon called metric fatigue.

Humana has already implemented an incentives program for physicians, and the investigators will work with them to design a program that just focuses on medication adherence. Physicians targeted for this pilot could also be enrolled in another Humana incentives program, but this incentives program will act independently of the other.

There are two treatment dimensions the investigators will test via random assignment at the practice level:

  1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
  2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.

In a previous study to increase uptake of colonoscopies among employees at a partner firm, the investigators found that using a post it note to catch the attention of the employee statistically significantly increased colonoscopy uptake over a control group. The investigators will also employ an eye catching method in the proposed pilot. When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. They will be encouraged to include the patient sheet in their chart as a reminder to discuss medication adherence with their patient the next time they see them. For half of our arms, the investigators will make the patient sheets a bright, non-white, color, in order to futher draw the physicians' attention to that specific paper in their chart.

Our experimental arms will be:

  1. Comprehensive incentives + comprehensive communication
  2. Comprehensive incentives + comprehensive communication + printed on bright non-white paper
  3. Focused incentives + focused communication (one for all three drug classes)
  4. Focused incentives + focused communication + printed on bright non-white paper (one for all three drug classes)
  5. Comprehensive communiation
  6. Comprehensive communication + printed on bright non-white paper
  7. Control arm: no communication + no incentives

The investigators hypothesize that physicians who receive focused incentives and focused communications will have more patients with increased medication adherence than physicians who receive comprehensive incentives and comprehensive communications. The investigators also hypothsize that physicians who receive patient sheets using bright, non-white paper will have more patients with increased medication adherence than physicians who receive plain white patient sheets.

Being tested
Increasing Medication Adherence through Physician Incentives and Messaging
Keywords
medication adherence, diabetes, hypertension, cholesterol, statins
Medical subject headings
Medication Adherence, Diabetes Mellitus, Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Increasing Medication Adherence through Physician Incentives and MessagingOther

    Also called Adherence

    There are two treatments:

    1. Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
    2. Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.

    When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart.

Study groups in NCT01603329
Study groupRoleWhat they receive
Comprehensive incentives + comprehensive communicationExperimentalPhysicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Comp incentives + comp communication + non-white paperExperimentalPhysicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Focused incentives + focused com for oral diabetes medicationExperimentalPhysicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Foc incentives + foc comm for Diabetes + non-white paperExperimentalPhysicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Focused incentives + focused comm for hypertension medsExperimentalPhysicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Foc incentives + comm for hypertension meds + non-white paperExperimentalPhysicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Focused incentives + focused comm for cholesterol medsExperimentalPhysicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Foc incentives +comm for cholesterol meds + non-white paperExperimentalPhysicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Comprehensive communiationExperimentalPhysicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Comprehensive communication + non-white paperExperimentalPhysicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging
Control ArmExperimentalPhysicians and their patient adherence is tracked, but they receive no intervention.
Receives: Other: Increasing Medication Adherence through Physician Incentives and Messaging

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Medication Adherence

    The investigators will see how the treatment arms affect the targeted physicians' patients medication adherence for oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.

    Measured: Up to two years

Secondary outcomes (2)
  1. Demographic Controls for Physicians

    The investigators will see if our targeted physicians' demographic controls affect their patients' medication adherence rates before and after treatment.

    Measured: Up to two years

  2. Demographic Controls for Patients

    The investigators will see how demographic controls for patients affect our targeted physicians' patients' medication adherence.

    Measured: Up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2012 (estimated)
  2. Study startJun 2012
  3. Primary completionFeb 2014
  4. Study completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
734 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01603329
Sponsor's protocol ID
007
Status last verified
Oct 2015
First submitted
16 May 2012
Last updated
23 Oct 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Increasing Medication Adherence through Physician Incentives and Messaging in people with Medication Adherence, run by National Bureau of Economic Research, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Medication Adherence (time frame: Up to two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in